Authors

Latest:

Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

Ted Huang, MD

Latest:

There and Back…

One of my teachers in medical school was fond of saying, "Internal medicine isn't sexy." Hematology/ oncology is no exception to this rule. Certainly, it is not as glamorous as cardiology or as hands-on as gastroenterology.

Ted Okon

Latest:

Ted Okon Foresees a Shortage of Oncologists in the Future

Ted Okon Explains Why he Foresees a Shortage of Oncologists in the Future

Teodora Kolarova, Harvard Medical Student

Latest:

Organization Rallies Global Oncology Community to Eliminate Cancer Health Disparities

Today, more than half of new cancer cases and over two-thirds of cancer deaths occur in low- and middle-income countries.

Terence Friedlander, MD

Latest:

Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial Cancer

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Terence M. Williams MD, PhD

Latest:

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Terence T. Sio, MD, MS

Latest:

Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Teresa K. Woodruff, PhD

Latest:

Dr. Woodruff on Oncofertility Insurance Coverage

Dr. Teresa Woodruff from Feinberg School of Medicine, Northwestern University, Discusses Oncofertility Insurance Coverage

Teresa Macarulla, MD

Latest:

Dr. Macarulla Discusses Rapid Progressors in the POLO Trial

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

Teresa Macarulla, MD, PhD, Vall d'Hebron Institute

Terrence J. Bradley, MD

Latest:

Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia Vera

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Terri Cullen

Latest:

Five Steps to Financial Security for Fellows

The first few years after medical school can seem financially suffocating for young physicians.

Terri Febbraro, MD

Latest:

Dr. Terri Febbraro on the Inverse Correlation Between Time on Chemotherapy and OS

Terri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.

Terri Woodard, MD

Latest:

Dr. Terri Woodard on Preservative Measures for Women With Ovarian Cancer

Terri Woodard, MD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses if conservative management for women with ovarian cancer is warranted.

Terrill Jordan

Latest:

Plans to Implement Fee-for-Value Models in Oncology

Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

Terrill Jordan, LLM, JD, MAcc

Latest:

Incorporating Precision Medicine into Oncology

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Terry B. Gernsheimer, MD

Terry Gernsheimer, MD, Fred Hutchingson Cancer Research Center

Terry L. Evans, MD

Latest:

Dr. Evans on the Tolerability of CDK4/6 Inhibitors in HR+ Breast Cancer

Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Terry P. Mamounas, MD, MPH

Latest:

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.